Demo Sign up Log In

Vertex Pharmaceuticals (VRTX)

Cost of Revenue

$1.76B

TTM · Period ending: Jun 30, 2026 · USD

VRTX Cost of Revenue

Latest reported$1.76Bperiod endingJun 30, 2026

Latest reported$1.76Bperiod endingJun 30, 2026

VRTX TTM Cost of Revenue ($0.00 → $1.76B)

TTM cost of revenue

High-resolution chart · PNG

VRTX cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Vertex Pharmaceuticals Cost of Revenue — Trailing twelve months (TTM) (USD)
Period ending	Cost of Revenue (USD)
Jun 30, 2001	7,953,000
Mar 31, 2001	6,022,000
Dec 31, 2000	4,082,000
Sep 30, 2000	-4,280,000
Jun 30, 2000	-4,113,000
Mar 31, 2000	-3,303,000
Dec 31, 1999	-3,400,000
Sep 30, 1999	-3,800,000
Jun 30, 1999	-3,900,000
Mar 31, 1999	-4,800,000
Dec 31, 1998	-4,500,000
Sep 30, 1998	-4,100,000
Jun 30, 1998	-4,000,000
Mar 31, 1998	-3,700,000
Dec 31, 1997	-3,600,000
Sep 30, 1997	-3,300,000
Jun 30, 1997	-3,100,000
Mar 31, 1997	-3,200,000
Dec 31, 1996	-3,200,000
Sep 30, 1996	-3,500,000
Jun 30, 1996	-3,700,000
Mar 31, 1996	-3,500,000
Dec 31, 1995	-3,700,000
Sep 30, 1995	-3,700,000
Jun 30, 1995	-3,500,000
Mar 31, 1995	-3,700,000
Dec 31, 1994	-3,600,000
Sep 30, 1994	-3,700,000
Jun 30, 1994	-3,800,000
Mar 31, 1994	-3,800,000
Dec 31, 1993	-3,700,000
Sep 30, 1993	-3,300,000
Jun 30, 1993	-3,100,000
Mar 31, 1993	-200,000
Dec 31, 1992	0
Sep 30, 1992	200,000
Jun 30, 1992	500,000
Mar 31, 1992	-2,000,000
Dec 31, 1991	-1,400,000
Sep 30, 1991	-900,000
Jun 30, 1991	-500,000
Mar 31, 1991	0
Dec 31, 1990	0

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.